论文部分内容阅读
为了探讨两种具有协同作用的细胞因子共转染的瘤苗是否具有更好的抗肿瘤作用，我们将ＴＮＦ－α基因和ＩＬ－２基因转染Ｂ１６黑色素瘤细胞，获得同时分泌ＩＬ－２和ＴＮＦ的Ｂ１６细胞克隆株（命名为Ｂ１６－ＩＬ－２＋－ＴＮＦ－α＋细胞），并观察了其体内致瘤性和瘤苗效果。结果发现，Ｂ１６－ＩＬ－２＋－ＴＮＦ－α＋细胞的体内致瘤性显著低于ＴＮＦ－α基因或ＩＬ－２基因单独转染的Ｂ１６细胞；而且，事先接种Ｂ１６－ＩＬ－２＋－ＴＮＦ－α＋细胞的小鼠能抵抗再接种的野生型肿瘤细胞的生长，表明其具有更佳的瘤苗效果。
To investigate whether two co-transfected tumors with synergistic cytokines have better anti-tumor effects, we transfected TNF-α and IL-2 genes into B16 melanoma cells and obtained IL-2 and IL-2 simultaneously. B16 cell clonal strain of TNF (named B16-IL-2+-TNF-α+ cells), and its in vivo tumorigenicity and tumor vaccine efficacy were observed. As a result, it was found that the in vivo tumorigenicity of B16-IL-2+-TNF-α+ cells was significantly lower than that of the B16 cells transfected with the TNF-α gene or the IL-2 gene alone; furthermore, B16-IL-2+-TNF-α+ was inoculated in advance. The cells of the mice were able to resist the growth of the re-inoculated wild-type tumor cells, indicating that they have a better tumor vaccine effect.